Friday, 16 June 2017 657 loarthritis (SpA) is needed to strengthen patient-level research in non-experimental clinical settings. A research network collaboration of registries collecting data on patients with SpA, "EuroSpA" offers opportunities to enhance research capabilities in the real world setting. Objectives: To assess patient numbers, data extent and completeness in European SpA registries and establish an international research collaboration and common data set to address key data gaps for SpA patients treated in routine clinical practice. Methods: The "EuroSpA" research network collaboration was established between registries collecting data on SpA patients. A survey was conducted via email and follow-up interviews April-December 2016 to assess patient numbers, data availability and completeness in participating registries. Our survey tool was based on key variables identified through literature review and expert interviews. Results: 14 European rheumatology registries submitted information on their data covering approximately 63479 SpA patients, including patients with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) (Table) .
Data coverage was comprehensive for comorbidities, demographic and treatment variables, but limited for imaging and in PsA for skin and nail manifestations (figure).
Conclusions:
A European research collaboration network of SpA registries, "EuroSpA", including ≈ 63500 SpA patients enables the collection of key patient variables and strengthens research through increased patient numbers and cross-country comparative research. While core disease activity measures for SpA patients are widely collected, an enhanced standardized core dataset could strengthen future collaboration. PubMed (1950 to December 2016 , Embase, Web Of Science, and manual searches of references lists. We included observational studies and randomized trials comparing disease activity scores, specifically BASDAI and ASDAS, between men and women with SpA. Studies quality was determined in line with the STROBE statement for observational studies and CONSORT statement for RCT, considering <50% positive items as low quality. Randomized effects were performed to report the mean difference (95% confidence interval) by gender, and heterogeneity was measured via I 2 statistic in order to check the results robustness. Results: From 672 identified studies 18 cross-sectional studies, 3 cohort, 2 case-control studies, and 1 RTC reported sex-stratified BASDAI and ASDAS. ASDAS was evaluated in 3,758 patients (36.5% women) in 9 studies, and BASDAI included 12,329 patients (34.3% women) in 24 studies. In a metanalysis of mean difference BASDAI including 19 studies the mean difference was 0.56 (95% CI: 0.47, 0.66) and I 2 =43%, indicating a significantly higher disease activity in women ( Figure) . In a metanalysis of 7 studies ASDAS the mean difference was 0.06 (95% CI: -0.04, 0.16) and I 2 =41%, not showing statistically significant differences.
We identified relevant sex differences in disease activity according to BASDAI with higher disease activity in women, but not according to ASDAS. In SpA, women present more peripheral arthritis and higher pain, which may influence the BASDAI score, mainly based on patient-self-report measures. It is important to recognize these differences that may influence management decisions based on disease activity measures. ). The mean number of consultations prior to diagnosis was 2.6; 3.0; 2.0 and 3.4, respectively. Patients stated the onset of the first ax-SpA symptoms was at mean 24.4 years of age, with diagnosis at mean 32.9 years of age, translating into a mean DD of 8.5 years. For 25% of patients DD was >12 years, whereas a DD of <2 years was found in only 25% of respondents. Mean DD for patients whose first symptoms appeared before 2009 was 9.5 years, whereas for patients whose first symptoms appeared after that date it was significantly reduced to 2.5 years.
The mean delay in diagnosis ax-SpA in Spain is above 8 years.
Patients make a large number of visits to a variety of specialist physicians before they are diagnosed, which could point to proof of wrong referrals by primary care. However, DD has fallen drastically (to a mean 2. Background: Spondyloarthropathies (SpAs) are a group of auto-inflammatory diseases, with overlapping symptoms, that include ankylosing spondylitis (AS), psoriatic arthritis (PsA), undifferentiated spondyloarthritis (Und SpA), enteropathic arthritis, and reactive arthritis (1). Objectives: To characterize the disease in a large Colombian cohort with SpAs, assessing differences in its classification, clinical manifestations, laboratory results, radiographic changes, and treatment, according to the type of SpA. Methods: A cross-sectional study was conducted in 621 patients with SpAs, in whom sociodemographic, clinical and therapeutic characteristics were analyzed based on the type of diagnosis. Statistical association was examined by means of Chi-square tests, Fisher's exact test, Mann-Whitney test, and logistic regression analyses. In all cases, a p value <0.05 was considered significant. Results: Out of the 621 patients included, AS was observed in 54,7%, PsA in 35,7%, and Und SpA in 9,5%. AS was positively associated to male gender (OR 2.05 95%IC 1.5-2.8), younger age at onset, axial involvement , radiographic sacroilitis , and HLA-B27 positivity (OR 2.3 95%IC 1.5-3.5). PsA was associated to female gender, older age at onset, arthritis, and peripheral involvement. According to the therapeutic approach, more use of conventional DMARD therapy was found in PsA and Und SpA, while more use of biology therapy in AS. 
